Critical Path for Parkinson's Consortium: Advancing Drug Development Tools and Regulatory Science for PD therapeutic trials

被引：0

作者：

Romero, K. ^{[1
]}

Akalu, M. ^{[1
]}

Alexander, R. ^{[2
]}

Bloem, B. R. ^{[4
]}

Boroojerdi, B. ^{[3
]}

Burn, D. ^{[5
]}

Cedarbaum, J. ^{[6
]}

Conrado, D. ^{[1
]}

Dexter, D. T. ^{[7
]}

Dorsey, E. R. ^{[8
,12
]}

Facheris, M. ^{[9
]}

Fischer, T. ^{[10
]}

Frasier, M. ^{[11
]}

Gallagher, J. ^{[7
]}

Gordon, M. Forrest ^{[12
]}

Grosset, D. ^{[13
]}

Hill, D. ^{[12
]}

Ho, C. ^{[14
]}

Hu, M. T. ^{[15
]}

Kieburtz, K. ^{[8
,12
]}

Lassen, A. B. ^{[16
]}

Lawson, R. ^{[5
]}

Macha, S. ^{[17
]}

Marek, K. ^{[18
]}

Taylor, K. ^{[19
]}

Russell, D. ^{[18
]}

Seibyl, J. ^{[18
]}

Stafford, B. ^{[1
]}

Stebbins, G. ^{[20
]}

Venuto, C. ^{[8
,12
]}

Williams-Gray, C. ^{[21
]}

Yarnall, A. ^{[5
]}

Stephenson, D. ^{[1
]}

机构：

[1] Crit Path Inst, Tucson, AZ USA

[2] Takeda, Tokyo, Japan

[3] UCB Pharma, Brussels, Belgium

[4] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[5] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England

[6] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA

[7] Parkinsons UK, London, England

[8] Univ Rochester, Rochester, NY 14627 USA

[9] AbbVie Inc, N Chicago, IL USA

[10] Sanofi, Paris, France

[11] Michael J Fox Fdn, New York, NY USA

[12] Advisor CPP, Toronto, ON, Canada

[13] Univ Glasgow, Glasgow, Lanark, Scotland

[14] Denali Therapeut, San Francisco, CA USA

[15] Univ Oxford, Oxford, England

[16] Lundbeck, Copenhagen, Denmark

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Inst Neurodegenerat Disorders, New Haven, CT USA

[19] Roche, Basel, Switzerland

[20] Rush Univ, Advisor CPP, Chicago, IL 60612 USA

[21] Univ Cambridge, Cambridge, England

来源：

MOVEMENT DISORDERS | 2019年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S17 / S17

页数：1

共 46 条

[1] Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson's Consortium
Stephenson, D.
Kopil, C.
Mueller, M.
Mabrouk, O.
Kocherla, H.
Comley, R.
Yee, K.
Dam, T.
Pagano, G.
Seibyl, J.
Marek, K.
Simuni, T.
MOVEMENT DISORDERS, 2024, 39 : S324 - S324
[2] Critical Path for Parkinson's: Catalyzing Innovation for Parkinson's Clinical Trials through Data Sharing and Regulatory Science
Stephenson, Diane
Akalu, Mussie
Alexander, Robert
Bloem, Bastiaan
Boroojerdi, Babak
Bravi, Daniele
Burn, David
Cedarbaum, Jesse
Conrado, Daniela
Dorsey, E. Ray
Facheris, Maurizio
Fischer, Tanya
Frasier, Mark
Gallagher, Jill
Gordon, Mark
Graff, Ole
Grosset, Donald
Sheikh, Zulfiqar Haider
Hill, Derek
Ho, Carole
Hu, Michele
Hynds, Renee
Kieburtz, Karl
Lawson, Rachael
Macha, Sreeraj
Manolis, Efthymios
Marek, Kenneth
Matthews, Dawn
Nicholas, Timothy
Podskalny, Gerald
Post, Anke
Romero, Klaus
Russell, David
Seibyl, John
Stafford, Bob
Stebbins, Glenn
Tome, Maria
Venuto, Charles
Williams-Gray, Caroline
Yarnall, Alison
Dexter, David
NEUROLOGY, 2019, 92 (15)
[3] Data Driven Paths to Advancing Precision Medicine Strategies for Parkinson's Disease: Critical Path for Parkinson's Consortium
Muller, M.
Dexter, D.
Cosman, J.
Zadikoff, C.
Ali, S.
Barwick, N.
Bloem, B.
Boroojerdi, B.
Burton, J.
Carroll, C.
Cedarbaum, J.
Dam, T.
Dawkins, P.
Grosset, D.
Hanan, N.
Hill, D.
Hu, M.
Jennings, D.
Jones, S.
Kieburtz, K.
Lawson, R.
Lee, K.
Marek, K.
Matthews, H.
Mehrotra, N.
Molinuevo, J.
Muglia, P.
Naito, A.
Pagano, G.
Sardi, S.
Schwarzschild, M.
Simen, A.
Simuni, T.
Stebbins, G.
Venuto, C.
Williams-Gray, C.
Stephenson, D.
MOVEMENT DISORDERS, 2021, 36 : S149 - S150
[4] The Critical Path Institute's Approach to Precompetitive Sharing and Advancing Regulatory Science
Woosley, R. L.
Myers, R. T.
Goodsaid, F.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) : 530 - 533
[5] Transporters in drug development: advancing on the Critical Path
Huang, Shiew-Mei
Woodcock, Janet
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) : 175 - 176
[6] Transporters in drug development: advancing on the Critical Path
Shiew-Mei Huang
Janet Woodcock
Nature Reviews Drug Discovery, 2010, 9 : 175 - 176
[7] C-Path's Duchenne Regulatory Science Consortium: Accelerating drug development for Duchenne muscular dystrophy
Belfiore-Oshan, R.
Aggarwal, V.
Sivakumaran, S.
Corey, D.
Ollivier, C.
Romero, K.
Vandenborne, K.
Kim, S.
Morales, J.
Lingineni, K.
Martinez, T.
NEUROMUSCULAR DISORDERS, 2022, 32 : S128 - S128
[8] The Critical Path for Parkinson's Consortium Approach to Developing Consensus Recommendations for Neuroimaging Biomarkers Appropriate for use in Parkinson's Disease Drug Development
Muller, M.
Comley, R.
Eberling, J.
Kazmi, H.
Kustermann, T.
Maguire, P.
Marek, K.
McGinnity, C.
Minchik, M.
Parker, C.
Passamonti, L.
Rousset, O.
Russell, D.
Salinas, C.
Seibyl, J.
Sivakumaran, S.
Stoessl, J.
Strafella, A.
Tosun-Turgut, D.
Wang, Y.
Stephenson, D.
Pagano, G.
MOVEMENT DISORDERS, 2023, 38 : S701 - S701
[9] Critical path for Parkinson's, I: Data sharing and regulatory science in catalyzing innovation for Parkinson's disease
Romero, K.
Burn, D.
Hu, M.
Yarnell, A.
Gray, C. Williams
Marek, K.
Grosset, D.
Sutherland, M.
Isaac, M.
Bhattaram, A.
Sinha, V.
Gordon, M. F.
Muglia, P.
Slicker, L.
Hirst, W.
Facheris, M.
Posener, J.
Bani, M.
Corrigan, B.
Schindler, R.
Tsai, K.
Nicholas, T.
Cedarbaum, J.
Gallagher, J.
Ford, S.
Avilex, E.
Kern, V.
Arneric, S.
Stephenson, D.
Roach, A.
MOVEMENT DISORDERS, 2016, 31 : S673 - S673
[10] Global regulatory agencies support the use of dopamine transporter neuroimaging for subject selection in clinical trials targeting early stage parkinson's disease - on behalf of critical path for Parkinson's (CPP) Consortium
Stephenson, D.
Cedarbaum, J.
Eberling, J.
Facheris, M.
Grosset, D.
Gordon, M.
Hill, D.
Imam, S.
Kern, V.
Klein, G.
Matthews, D.
Muglia, P.
Roach, A.
Romero, K.
Russell, D.
Seibyl, J.
Slieker, L.
Somer, E.
Sur, C.
Xie, Z.
Marek, K.
MOVEMENT DISORDERS, 2017, 32

← 1 2 3 4 5 →